Use Of Ep4 Receptor Antagonists In The Treatment Of Il-23 Mediated Diseases

Abstract

This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a pharmaceutical composition for the treatment of immune disease or allergy which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of immune disease or allergy in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof.


Claims
IPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Oct 4, 2016
  • Application: Feb 22, 2011
    US US 201113580323 A
  • Priority: Feb 22, 2011
    US US 201113580323 A
  • Priority: Feb 22, 2011
    JP 2011000994 W
  • Priority: Feb 22, 2010
    US US 28250610 P

Download Citation


Sign in to the Lens

Feedback